Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px download
Document › Details

Forge Therapeutics, Inc.. (8/29/17). "Press Release: Forge Therapeutics and Evotec to Present Preclinical Data on Novel Antibiotic Program at 2017 ASM/ESCMID Conference". San Diego, CA.

Organisations Organisation Forge Therapeutics Inc.
  Organisation 2 Evotec AG
  Group Evotec (Group)
Products Product LpxC inhibitor
  Product 2 preclinical research
Index term Index term Forge Therapeutics–Evotec: drug discovery services, 201612– collab strategic alliance lead optimisation of LpxC inhibitors by Evotec
     


Forge Therapeutics, Inc., (Forge) and its strategic alliance partner Evotec AG (Evotec), announced today that the companies will present two posters on Forge's LpxC antibiotic program at the 2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. The scientific conference is being held September 6-7, 2017 at the Boston Park Plaza Hotel in Boston, MA.

Poster Presentations:

Poster Title: In Vitro Characterization of Non-hydroxamate LpxC Inhibitors
Poster Board Number: 50
Wednesday, September 6, 2017 3:45 PM ET - 4:45 PM ET

Poster Title: In Vivo Characterization of Non-hydroxamate LpxC Inhibitors
Poster Board Number: 51
Thursday, September 7, 2017 3:45 PM ET - 4:45 PM ET

The abstracts related to the poster presentations are available through the ASM/ESCMID website: https://www.asm.org/images/Meetings/ASM-ESCMID/Poster%20Presentation%20Abstracts%20for%20the%20web2.pdf


About ASM/ESCMID

Antimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority by National and International bodies. There are relatively few agents in developmental pipelines and a paucity of identified microbiological targets that can be exploited for drug development. Co-sponsored by the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), this multidisciplinary meeting will address the challenges, opportunities and current requirements for antimicrobial drug development for AMR.


About LpxC and the 'Superbug' Epidemic

Millions of people around the globe have become infected with bacteria that are resistant to current antibiotic treatments, or 'superbugs', creating a global health epidemic. An estimated 700,000 worldwide deaths occur each year from these drug-resistant infections, and in the U.S. alone, an estimated 23,000 people die each year from antibiotic resistant infections. The biotechnology industry, leading government agencies and world leaders agree that the need for new antibiotics is urgent.

LpxC is an attractive and highly sought after antibiotic target – it is conserved across Gram-negative bacteria and not found in Gram-positive bacteria or human cells. Other LpxC inhibitors have been evaluated by biopharma in the past but chemistry limitations (e.g. hydroxamic acid) have yielded unsuitable compounds that suffer from poor drug-like properties. There are no approved therapeutics targeting LpxC.


About Forge Therapeutics

Forge Therapeutics is a privately-held biopharmaceutical company developing novel antibiotics to treat multi-drug resistant bacteria, or 'superbugs,' that have ignited a global health epidemic. With its proprietary chemistry approach, Forge develops small molecule inhibitors targeting metalloenzymes. Forge's lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow. Forge has discovered novel small molecule inhibitors of LpxC that are potent in vitro, efficacious in vivo, and effective against drug resistant Gram-negative bacteria 'superbugs.' To complement its innovative approach to drug discovery, Forge has a capital efficient business model that utilizes a mix of non-dilutive and traditional funding sources to advance its programs, including LpxC. Forge has formed a strategic alliance with leading drug discovery alliance and development partnership company Evotec AG and has been awarded multiple government awards to address the global 'superbug' epidemic. In addition, Forge has amassed a rich intellectual property estate on metalloprotein inhibitors to protect its technology and pipeline. For further information, please visit the company's website www.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.


Forge Company Contact:
Info@ForgeTherapeutics.com

Forge Media Contact:
Amy Conrad
Juniper Point
amy@juniper-point.com
858-366-3243

   
Record changed: 2017-09-06

Advertisement

Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 600x60px

More documents for Forge Therapeutics Inc.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px download




» top

Advertisements

Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 22 Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture Berlin Partner HealthCapital BIO-Europe 2017 Germany November 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px 41 Picture EBD Group BioPharm America 2017 BPA Boston MA Save USD100 120x180px Picture BIO Deutschland EBDC 2017 Heidelberg 120x240px Picture EBD Group Bio-Europe 2017 BEU Berlin Germany November 120x80px